![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » PROVALIS'S LOSSES HIT £5.6M
PROVALIS'S LOSSES HIT £5.6M
October 20, 2005
MEDICAL diagnostics and pharmaceuticals group Provalis yesterday posted losses of £5.6m against sales of £10.4m. Frank Harding, chairman of the Deeside company, said, "The financial year ended June 30, 2005, was challenging, with some real successes but some disappointments. Although sales by the Medical Diagnostics and Pharmaceutical businesses were lower than anticipated, the medical diagnostics business in particular made good progress with operational and strategic developments."
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct